Home » Stocks » LMAT

LeMaitre Vascular, Inc. (LMAT)

Stock Price: $47.59 USD -3.20 (-6.29%)
Updated Mar 4, 2021 2:24 PM EST - Market open
Market Cap 1.07B
Revenue (ttm) 121.99M
Net Income (ttm) 18.80M
Shares Out 20.25M
EPS (ttm) 1.04
PE Ratio 45.75
Forward PE 42.74
Dividend $0.38
Dividend Yield 0.80%
Trading Day March 4
Last Price $47.59
Previous Close $50.78
Change ($) -3.20
Change (%) -6.29%
Day's Open 50.41
Day's Range 46.30 - 50.74
Day's Volume 149,685
52-Week Range 18.59 - 54.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 6 days ago

Shares of LeMaitre Vascular (NASDAQ:LMAT) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 47.83% over the past year to $...

GlobeNewsWire - 6 days ago

BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2020 results and announced an $0.11/share ...

GlobeNewsWire - 2 weeks ago

BURLINGTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in four upcoming investor conferences.

GlobeNewsWire - 1 month ago

BURLINGTON, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2020 financial results on Thursday, February ...

GlobeNewsWire - 2 months ago

BURLINGTON, Mass., Dec. 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in January.

Seeking Alpha - 2 months ago

The LeMaitre's corporate health partly depends on how much its sales reps can do to overcome current blocks, and how soon the pandemic ends.

Seeking Alpha - 2 months ago

LeMaitre has posted a strong quarter compounded by successful acquisition activity YTD, with little OPEX tied into profits in Q3. Management has widened the capital structure to be more debt i...

Zacks Investment Research - 2 months ago

Here are five top-ranked liquid stocks, Winnebago Industries, (WGO), Shutterstock (SSTK), Logitech (LOGI), Ituran Location and Control (ITRN), and LeMaitre Vascular (LMAT), that investors can ...

Other stocks mentioned: ITRN, LOGI, SSTK, WGO
Zacks Investment Research - 3 months ago

Here are four top-ranked liquid stocks, Winnebago Industries (WGO), Shutterstock (SSTK), Logitech (LOGI), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.

Other stocks mentioned: LOGI, SSTK, WGO
Zacks Investment Research - 3 months ago

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Insider Monkey - 3 months ago

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen U.S. Small Company Growth Composite P...

GlobeNewsWire - 3 months ago

BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at Jefferies Virtual London Healthcare Co...

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in November.

Seeking Alpha - 4 months ago

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

LeMaitre (LMAT) delivered earnings and revenue surprises of 76.19% and 13.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of LeMaitre Vascular (NASDAQ:LMAT) moved higher by 7.5% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 48.00% year over ye...

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2020 results and announced ...

Zacks Investment Research - 4 months ago

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2020 financial results on Thursday, October 29...

GuruFocus - 5 months ago

To increase the likelihood of unearthing high-quality companies, Benjamin Graham, the pioneer of value investing, recommended screening the market for stocks with a current ratio of more than ...

Other stocks mentioned: LPX, SWBI
GuruFocus - 5 months ago

To increase the likelihood of unearthing high-quality companies, Benjamin Graham, the pioneer of value investing, recommended screening the market for stocks with a current ratio of more than ...

Other stocks mentioned: LPX, SWBI
Zacks Investment Research - 5 months ago

LeMaitre Vascular is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 7 months ago

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

LeMaitre (LMAT) delivered earnings and revenue surprises of 440.00% and 59.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 7 months ago

BURLINGTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2020 results and announce...

Zacks Investment Research - 7 months ago

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

BURLINGTON, Mass., July 10, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2020 financial results on Thursday, July 23...

GlobeNewsWire - 8 months ago

BURLINGTON, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that it has acquired the business and assets of Artegraft, Inc. for $90.0 million, inclu...

The Motley Fool - 9 months ago

MSA Safety, Fresnius Medical Care, and LeMaitre Vascular are well-priced stocks on the rise with solid dividends.

Other stocks mentioned: MDT, FMS, MSA
Zacks Investment Research - 9 months ago

An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.

Other stocks mentioned: MGNX, QDEL, ZYXI
Seeking Alpha - 10 months ago

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -2.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

Catching The Bottom

Other stocks mentioned: GPC
GlobeNewsWire - 10 months ago

BURLINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, announced today Q1 2020 preliminary, unaud...

The Motley Fool - 1 year ago

We take a look at three small and promising healthcare companies across diagnostics, surgical products, and genetic testing.

Other stocks mentioned: FLGT, SMLR
Seeking Alpha - 1 year ago

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -1.05%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GuruFocus - 1 year ago

Rising earnings move share prices up.

Other stocks mentioned: DRE, SABR
Forbes - 1 year ago

Looking for a shopping list of stocks to add to your portfolio? Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their top stock ideas for the year.

Other stocks mentioned: DSGX, GD, GE, MA, MSM, OMC, PBI, WTER
Investors Business Daily - 1 year ago

Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs.

Other stocks mentioned: ALGN, EW, GMED, QDEL, RGEN, RMD
Zacks Investment Research - 1 year ago

EYE vs. LMAT: Which Stock Is the Better Value Option?

Other stocks mentioned: EYE
Seeking Alpha - 1 year ago

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

LeMaitre (LMAT) delivered earnings and revenue surprises of 19.05% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

BURLINGTON, Mass., Oct. 13, 2019 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), announced that it has acquired the biologic patch business of Admedus Ltd (ASX: AHZ) for $15.5 mi...

Zacks Investment Research - 1 year ago

EYE vs. LMAT: Which Stock Is the Better Value Option?

Other stocks mentioned: EYE
GuruFocus - 1 year ago

Chairman and CEO of Lemaitre Vascular Inc (30-Year Financial, Insider Trades) George W Lemaitre (insider trades) sold 66,037 shares of LMAT on 07/25/2019 at an average price of $34.45 a share.

Seeking Alpha - 1 year ago

LeMaitre Vascular Inc. (LMAT) CEO George LeMaitre on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

LeMaitre (LMAT) delivered earnings and revenue surprises of 9.52% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

About LMAT

LeMaitre Vascular designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Oct 19, 2006
CEO
George LeMaitre
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
LMAT
Full Company Profile

Financial Performance

In 2019, LMAT's revenue was $117.23 million, an increase of 11.05% compared to the previous year's $105.57 million. Earnings were $17.93 million, a decrease of -21.83%.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price forecast is 54.00, which is an increase of 13.48% from the latest price.

Price Target
$54.00
(13.48% upside)
Analyst Consensus: Buy